What is Pfizer's bosulif — revenues:?

Pfizer (PFE) reported bosulif — revenues: of $129M in Q1 2026.

How has Pfizer's bosulif — revenues: changed year-over-year?

Pfizer's bosulif — revenues: decreased by 14.6% year-over-year, from $151M to $129M.

What is the long-term trend for Pfizer's bosulif — revenues:?

Over 4 years (2021 to 2025), Pfizer's bosulif — revenues: has grown at a 3.1% compound annual growth rate (CAGR), from $540M to $611M.

What does bosulif — revenues: mean?

This metric represents the total net sales generated from the specific oncology pharmaceutical product line. It reflects the market adoption, pricing power, and clinical demand for this targeted therapy within the hematology-oncology portfolio. Monitoring this revenue stream provides insight into the product's lifecycle stage and its contribution to the company's overall specialty medicine segment.

Pfizer PFE Bosulif — Revenues:

Other product segments

Eliquis

$2.17B+12.6%

Prevnar Family

$1.69B+1.8%

Vyndaqel family

$1.6B+7.8%

Ibrance

$1.01B+3.2%

All Other Hospital and Biosimilars

$953M—

All other Primary Care

$654M+7.4%

Padcev

$591M+38.7%

All other Specialty Care

$579M+19.1%

Xtandi

$444M-3.1%

Oncology Biosimilars

$409M+54.9%

Royalty

$396M+28.6%

All other Oncology

$376M-0.3%

Nurtec ODT/Vydura

$353M+42.3%

Lorbrena

$305M+37.4%

Pfizer CentreOne

$289M+5.9%

Comirnaty

$232M-58.9%

Paxlovid

$219M-69.9%

Inlyta

$214M-2.3%

Sulperazon (Outside the U.S. and Canada)

$199M+21.3%

Adcetris

$190M-12.8%

Inflectra

$182M—

Abrysvo

$180M+37.4%

Xeljanz

$180M+40.6%

Braftovi/Mektovi

$174M+27.9%

Zavicefta (Outside the U.S. and Canada)

$150M+11.1%

Enbrel (Outside the U.S. and Canada)

$138M-1.4%

Octagam

$122M—

Tukysa

$122M+19.6%

Zithromax

$112M-29.1%

Orgovyx

$109M—

Genotropin

$93M—

FSME-IMMUN/TicoVac

$81M—

Elrexfio

$80M+33.3%

Cibinqo

$76M+31.0%

Talzenna

$50M+25.0%

Tivdak

$33M0.0%

Similar metrics at other companies

OGNOther Biosimilars — Revenue

$24M+380%

OGNOntruzant — Revenue

$5M-72.2%

AMGNBLINCYTO — Total revenues

$415M+12.2%

COLLBelbuca — Product revenues, net

$52.65M+1.9%

BMYReblozyl — Total Revenues

$555M+16.1%

OGNBrenzys — Revenue

$20M+42.9%

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+4.9%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$138.21B-3.7%

Enterprise value$200.88B-1.3%

P/E11.4×—

P/S2.2×-0.1×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

FCF margin18%+8.8pp

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's bosulif — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's bosulif — revenues:?: Pfizer (PFE) reported bosulif — revenues: of $129M in Q1 2026.
How has Pfizer's bosulif — revenues: changed year-over-year?: Pfizer's bosulif — revenues: decreased by 14.6% year-over-year, from $151M to $129M.
What is the long-term trend for Pfizer's bosulif — revenues:?: Over 4 years (2021 to 2025), Pfizer's bosulif — revenues: has grown at a 3.1% compound annual growth rate (CAGR), from $540M to $611M.
What does bosulif — revenues: mean?: This metric represents the total net sales generated from the specific oncology pharmaceutical product line. It reflects the market adoption, pricing power, and clinical demand for this targeted therapy within the hematology-oncology portfolio. Monitoring this revenue stream provides insight into the product's lifecycle stage and its contribution to the company's overall specialty medicine segment.